



nContact Launches New U.S. Corporate Website **www.ncontactsurgical.com**

Morrisville, NC – January 8, 2010 - nContact Surgical, Inc. (“nContact”), a leader in the development of minimally-invasive cardiac coagulation devices, announced today the launch of its new U.S. corporate website, www.ncontactsurgical.com. The site was designed with a new look to reflect nContact’s innovation and dedication in device development for treating heart arrhythmias that impact millions of people worldwide.

In addition to other related topics, the enhanced site provides an in-depth view of nContact’s *Numeris® Tethered and Guided Coagulation Systems with VisiTrax®*, including detailed images and animation videos. Information about nContact’s ongoing U.S. clinical trials for the treatment of longstanding persistent AF in open-chest concomitant procedures and symptomatic paroxysmal AF in closed-chest convergent procedures can also be found.

“The launch of our new U.S. website marks an important step for our company as we work to build awareness about our clinical trials in the United States among physicians and patients looking to explore investigational options for the treatment of AF,” said John P. Funkhouser, President and CEO of nContact. “The new website is an excellent technology reference source that shows how we are utilizing our technology and experiences to reach new markets.”

About nContact Surgical, Inc.

nContact is a medical device company founded in 2005 with the company mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The *Numeris® Coagulation System with VisiTrax®* is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, bi-atrial epicardial lesions on a beating heart.

To date, The *Numeris Coagulation System with VisiTrax* is indicated for the coagulation of cardiac tissue in the United States. nContact has initiated clinical studies for the treatment of AF in both open and closed chest procedures. The *Numeris Coagulation System with VisiTrax* has CE Mark approval in Europe for the specific indication for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter.

nContact, Inc.
1001 Aviation Parkway, Ste 400
Morrisville, NC 27560
T (919) 466-9810
F (919) 466-9811

Media Contacts
Angela Moser
nContact Surgical, Inc.
amoser@ncontactsurgical.com

Scott Lerman
The Ruth Group
T (646) 536-7013
slerman@theruthgroup.com